FDA Approves First-in-Class Schizophrenia Drug from BMS
- Posted by ISPE Boston
- On October 18, 2024
The FDA has approved Cobenify, an oral medication for the treatment of schizophrenia in adults. Cobenify represents the first new class of schizophrenia medicine in several decades and introduces a fundamentally new approach to treating the illness. “Today’s landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more […]
Read More